X4 Pharmaceuticals (NASDAQ:XFOR) Stock Crosses Below Fifty Day Moving Average – Should You Sell?

Posted by Stanley Muller on Nov 4th, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) shares crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $3.30 and traded as low as $3.14. X4 Pharmaceuticals shares last traded at $3.17, with a volume of 630,984 shares.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on XFOR shares. Weiss Ratings downgraded shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th. Wells Fargo & Company initiated coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, X4 Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $11.25.

Get Our Latest Report on X4 Pharmaceuticals

X4 Pharmaceuticals Trading Down 5.4%

The firm has a fifty day simple moving average of $3.30 and a 200-day simple moving average of $3.79. The firm has a market cap of $314.31 million, a P/E ratio of -2.64 and a beta of 0.47. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 11.02.

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. The firm had revenue of $8.81 million for the quarter, compared to the consensus estimate of $2.42 million. On average, equities research analysts expect that X4 Pharmaceuticals, Inc. will post -0.67 earnings per share for the current year.

Insider Transactions at X4 Pharmaceuticals

In other news, Chairman Adam Craig sold 47,436 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the transaction, the chairman directly owned 328,651 shares of the company’s stock, valued at $1,459,210.44. This represents a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO David Kirske sold 11,767 shares of X4 Pharmaceuticals stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total value of $33,653.62. Following the sale, the chief financial officer owned 155,983 shares in the company, valued at $446,111.38. This trade represents a 7.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 83,779 shares of company stock worth $353,387 in the last 90 days. Insiders own 1.13% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alps Advisors Inc. increased its position in shares of X4 Pharmaceuticals by 36.2% in the third quarter. Alps Advisors Inc. now owns 130,424 shares of the company’s stock worth $378,000 after purchasing an additional 34,698 shares during the last quarter. WINTON GROUP Ltd lifted its position in X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock valued at $67,000 after purchasing an additional 3,800 shares during the last quarter. Squarepoint Ops LLC bought a new stake in X4 Pharmaceuticals during the second quarter valued at approximately $313,000. AXQ Capital LP bought a new stake in X4 Pharmaceuticals during the second quarter valued at approximately $107,000. Finally, Wellington Management Group LLP purchased a new position in X4 Pharmaceuticals in the 2nd quarter worth approximately $242,000. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

(Get Free Report)

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.